|
09 Sep 2025 |
CreditAccess Grameen
|
Consensus Share Price Target
|
1336.70 |
1360.20 |
- |
1.76 |
buy
|
|
|
|
|
22 May 2023
|
CreditAccess Grameen
|
ICICI Securities Limited
|
1336.70
|
1425.00
|
1257.60
(6.29%)
|
Target met |
Buy
|
|
|
CA Grameen, in its maiden analyst day (held on 18th May’23), has unveiled its journey to reach AUM of Rs500bn, implying 20-25% CAGR over the next 4-5 years, from Rs200bn in March’23. More importantly, the management highlighted that it has now built a self-sustainable business model with 20-25% AUM growth and >20% RoE.
|
|
19 May 2023
|
CreditAccess Grameen
|
Axis Direct
|
1336.70
|
1315.00
|
1220.10
(9.56%)
|
Target met |
Buy
|
|
|
We value CAGrameen at 3x Sep'24E BV to arrive at a target price of Rs 1,315/share, implying an upside of 11% from CMP.
|
|
17 May 2023
|
CreditAccess Grameen
|
ICICI Securities Limited
|
1336.70
|
1425.00
|
1171.50
(14.10%)
|
Target met |
Buy
|
|
|
E CreditAccess Grameen (CA Grameen) in Q4FY23 became the first NBFC-MFI to cross Rs200bn AUM in India and simultaneously demonstrated scalability with best-in- class asset quality metrics and profitability. Its industry-leading RoA / RoE at 5.5% / 24.0% respectively during Q4FY23 reflects its resilient business model.
|
|
17 May 2023
|
CreditAccess Grameen
|
Axis Direct
|
1336.70
|
1315.00
|
1171.50
(14.10%)
|
Target met |
Buy
|
|
|
Recommendation: We maintain our BUY recommendation on the stock.
|
|
17 May 2023
|
CreditAccess Grameen
|
ICICI Direct
|
1336.70
|
1375.00
|
1171.50
(14.10%)
|
Target met |
Buy
|
|
|
|
|
01 Apr 2023
|
CreditAccess Grameen
|
ICICI Direct
|
1336.70
|
1100.00
|
915.20
(46.06%)
|
Target met |
Buy
|
|
|
|
|
08 Feb 2023
|
CreditAccess Grameen
|
Axis Direct
|
1336.70
|
1215.00
|
956.60
(39.73%)
|
Target met |
Buy
|
|
|
Recommendation: We maintain our BUY recommendation on the stock.
|
|
08 Feb 2023
|
CreditAccess Grameen
|
ICICI Securities Limited
|
1336.70
|
1300.00
|
956.60
(39.73%)
|
Target met |
Buy
|
|
|
CreditAccess Grameen (CAGL) continued to deliver industry-leading performance as reflected in Q3FY23 RoA / RoE at 4.6% / 18.8%, respectively - surpassing pre-covid level. Notably, Board approval for the extension of Mr. Udaya Kumar Hebbar as MD & CEO for another 2 years, post the expiry of his current term on June’23 (subject to shareholder approval), would ensure management continuity at the top.
|
|
13 Dec 2022
|
CreditAccess Grameen
|
Monarch Networth Capital Limited
|
1336.70
|
1315.00
|
909.95
(46.90%)
|
Target met |
Buy
|
|
|
|
|
12 Dec 2022
|
CreditAccess Grameen
|
ICICI Securities Limited
|
1336.70
|
1300.00
|
900.55
(48.43%)
|
Target met |
Buy
|
|
|
We reiterate our BUY rating on CreditAccess Grameen (CA Grameen) and believe the sharp correction (>10%) in stock price over past 15 days is unwarranted considering the strong H1FY23 performance and sector tailwinds.
|